Expansion of Sandhoff Disease Drug Pipeline with Key Companies

DelveInsight Business Research LLP has announced the expansion of the Sandhoff Disease clinical trial drug development pipeline, with contributions from five or more key companies. The development pipeline now includes a range of therapies, including IB1001, Zavesca (Miglustat), TSHA-101, and Miglustat, among others.

In September 2026, the National Tay-Sachs and Allied Diseases Association (NTSAD) and the American Society of Gene & Cell Therapy (ASGCT) launched the inaugural NTSAD-ASGCT Translational Research Fellowship Program. This program aims to fund translational and near-clinical research focused on rare neurogenetic diseases, including Sandhoff disease. The fellowship will provide a $50,000 award annually for up to two years.

The report from DelveInsight highlights that the Sandhoff Disease pipeline is robust, with five or more active players working on developing therapies. Leading companies in this space include IntraBio, Sanofi, Polaryx Therapeutics, and Azafaros. The report also identifies promising pipeline therapies such as IB1001, which is an orally administered modified amino acid developed by IntraBio. In vivo studies have shown that N-acetyl-L-leucine, the active isomer of N-acetyl-DL-leucine, can restore neuronal function and protect against or delay disease progression in multiple neurological circuits of the brain.

Another therapy in the pipeline is Venglustat, an investigational oral therapy developed by Sanofi. Currently in Phase III clinical trials, Venglustat has the potential to slow the progression of Sandhoff disease by inhibiting abnormal glycosphingolipid (GSL) accumulation.

The DelveInsight report provides detailed insights into the therapeutic assessment of pipeline drugs by route of administration, including oral, parenteral, intravenous, subcutaneous, and topical routes. It also segments the products based on molecule types such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapy.

The report covers the therapeutic assessment of pipeline drugs by clinical stages, including discovery, preclinical, Phase I, Phase II, and Phase III. It also includes information on late-stage products (Phase III), mid-stage products (Phase II), and early-stage products (Phase I). Additionally, the report details inactive products, key companies, key products, unmet needs, market drivers, and barriers, as well as future perspectives and analyst views.

Overall, the expansion of the Sandhoff Disease clinical trial drug development pipeline reflects the ongoing efforts to address the unmet needs in the treatment of this rare lysosomal storage disease. With multiple therapies in various stages of development, there is hope for improved outcomes for patients suffering from Sandhoff disease.